{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:14:41Z","timestamp":1792088081807,"version":"4.4.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.eclinm.2023.102060","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T13:26:35Z","timestamp":1688563595000},"page":"102060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Trends in risk for therapy-related myelodysplastic syndrome\/acute myeloid leukemia after initial chemo\/immunotherapy for common and rare lymphoid neoplasms, 2000\u20132018"],"prefix":"10.1016","volume":"61","author":[{"given":"Lindsay M.","family":"Morton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle E.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha S.","family":"Linet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara J.","family":"Schonfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragati G.","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole H.","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Sasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gra\u00e7a M.","family":"Dores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.eclinm.2023.102060_bib1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"15","key":"10.1016\/j.eclinm.2023.102060_bib2","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1182\/blood-2012-08-448068","article-title":"Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008","volume":"121","author":"Morton","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102060_bib3","first-page":"1481","article-title":"Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study","volume":"91","author":"Moser","year":"2006","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102060_bib4","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.2010.28.9777","article-title":"Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma","volume":"29","author":"Tarella","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102060_bib5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJM199001043220102","article-title":"Leukemia following Hodgkin's disease","volume":"322","author":"Kaldor","year":"1990","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.eclinm.2023.102060_bib6","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/jnci\/86.19.1450","article-title":"Risk of leukemia following treatment for non-Hodgkin's lymphoma","volume":"86","author":"Travis","year":"1994","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102060_bib7","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1200\/JCO.1994.12.5.1063","article-title":"Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage","volume":"12","author":"van Leeuwen","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102060_bib8","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eclinm.2023.102060_bib9","series-title":"SEER cancer statistics review, 1975-2016","author":"Howlader","year":"2019"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102060_bib10","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eclinm.2023.102060_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.942122","article-title":"Analysis and prediction of relative survival trends in patients with non-Hodgkin lymphoma in the United States using a model-based period analysis method","volume":"12","author":"Xie","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102060_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41392-020-0113-2","article-title":"Advances in targeted therapy for\u00a0malignant lymphoma","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct Targeted Ther"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102060_bib13","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-019-0752-3","article-title":"Novel and emerging therapies for B cell lymphoma","volume":"12","author":"Ayyappan","year":"2019","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.eclinm.2023.102060_bib14","series-title":"World Health organization classification of tumours of haematopoietic and lymphoid Tissues","author":"Jaffe","year":"2001"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102060_bib15","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/pbc.23385","article-title":"Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies","volume":"58","author":"Hudson","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102060_bib16","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1038\/s41375-019-0520-y","article-title":"Risk of therapy-related myelodysplastic syndrome\/acute myeloid leukemia after childhood cancer: a population-based study","volume":"33","author":"Advani","year":"2019","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102060_bib17","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1182\/blood-2006-11-051672","article-title":"Proposed classification of lymphoid neoplasms for epidemiologic research from the pathology working group of the international lymphoma Epidemiology consortium (InterLymph)","volume":"110","author":"Morton","year":"2007","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.eclinm.2023.102060_bib18","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1182\/blood-2010-06-289561","article-title":"InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions","volume":"116","author":"Turner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102060_bib20","series-title":"World Health organization classification of tumours of haematopoietic and lymphoid Tissues","author":"Swerdlow","year":"2008"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102060_bib21","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jamaoncol.2018.5625","article-title":"Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era","volume":"5","author":"Morton","year":"2019","journal-title":"JAMA Oncol"},{"issue":"20","key":"10.1016\/j.eclinm.2023.102060_bib22","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102060_bib23","series-title":"New malignancies among cancer survivors: SEER cancer registries, 1973-2000","article-title":"Methods","author":"Curtis","year":"2006"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102060_bib24","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/aje\/kwg278","article-title":"A\u00a0methodological issue in the analysis of second-primary cancer incidence in long-term survivors of childhood cancers","volume":"158","author":"Yasui","year":"2003","journal-title":"Am J Epidemiol"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102060_bib25","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102060_bib26","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1182\/blood-2004-08-3035","article-title":"Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha","volume":"105","author":"McLaughlin","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102060_bib27","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/modpathol.2011.158","article-title":"Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"25","author":"Zhou","year":"2012","journal-title":"Mod Pathol"},{"issue":"21","key":"10.1016\/j.eclinm.2023.102060_bib28","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1002\/cncr.29605","article-title":"Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia","volume":"121","author":"Short","year":"2015","journal-title":"Cancer"},{"issue":"33","key":"10.1016\/j.eclinm.2023.102060_bib29","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1200\/JCO.2010.29.1112","article-title":"Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype","volume":"28","author":"Morton","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.eclinm.2023.102060_bib30","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2011-05-355743","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndromes following multiple myeloma and its precursor disease (MGUS)","volume":"118","author":"Mailankody","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102060_bib31","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3816\/CLML.2010.n.076","article-title":"Ten years of improvement in the management of multiple myeloma: 2000-2010","volume":"10","author":"Harousseau","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102060_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112712","article-title":"Rapid progress in immunotherapies for multiple myeloma: an updated comprehensive review","volume":"13","author":"Nishida","year":"2021","journal-title":"Cancers"},{"issue":"1\u20132","key":"10.1016\/j.eclinm.2023.102060_bib33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cbi.2009.12.013","article-title":"Incidence and susceptibility to therapy-related myeloid neoplasms","volume":"184","author":"Leone","year":"2010","journal-title":"Chem Biol Interact"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102060_bib34","doi-asserted-by":"crossref","first-page":"e906","DOI":"10.1016\/S2352-3026(22)00289-7","article-title":"Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis","volume":"9","author":"Saleem","year":"2022","journal-title":"Lancet Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.eclinm.2023.102060_bib35","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/hon.2853","article-title":"High-risk follicular lymphoma: treatment options","volume":"39","author":"Kahl","year":"2021","journal-title":"Hematol Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102060_bib36","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1634\/theoncologist.2017-0037","article-title":"Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with follicular lymphoma grade 3a: evidence from a multicenter, retrospective study","volume":"23","author":"Mondello","year":"2018","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102060_bib37","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2146\/ajhp090328","article-title":"Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia","volume":"67","author":"Elefante","year":"2010","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.eclinm.2023.102060_bib38","article-title":"Navigating the evolving treatment landscape of diffuse large b-cell lymphoma","author":"Nastoupil","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102060_bib39","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11864-021-00857-w","article-title":"Novel biological insights and new developments in management of Burkitt lymphoma and high-grade B-cell lymphoma","volume":"22","author":"Lap","year":"2021","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102060_bib40","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11899-018-0457-7","article-title":"Novel therapies in acute lymphoblastic leukemia","volume":"13","author":"Phelan","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102060_bib41","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11899-021-00609-5","article-title":"Invited Review: will consolidation with ASCT be a thing of the past for MCL and PTCL?","volume":"16","author":"Broccoli","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102060_bib42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11864-019-0687-5","article-title":"Marginal zone lymphoma: state-of-the-art treatment","volume":"20","author":"Sindel","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.eclinm.2023.102060_bib43","first-page":"1","article-title":"Reducing treatment toxicity in Waldenstrom macroglobulinemia","author":"Sarosiek","year":"2021","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102060_bib44","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/bjh.17458","article-title":"How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sezary syndrome","volume":"195","author":"Sethi","year":"2021","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102060_bib45","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.abd.2020.12.007","article-title":"Mycosis fungoides and Sezary syndrome: focus on the current treatment scenario","volume":"96","author":"Sanches","year":"2021","journal-title":"An Bras Dermatol"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102060_bib46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jamaoncol.2015.4134","article-title":"Current therapy and new directions in the treatment of hairy cell leukemia: a review","volume":"2","author":"Sarvaria","year":"2016","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102060_bib47","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200310","article-title":"Prediction of risk for myeloid malignancy in clonal hematopoiesis","volume":"2","author":"Weeks","year":"2023","journal-title":"NEJM Evid"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102060_bib48","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood.2021010764","article-title":"What's new in the pathogenesis and treatment of therapy-related myeloid neoplasms","volume":"138","author":"Voso","year":"2021","journal-title":"Blood"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023002377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023002377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:20:45Z","timestamp":1762899645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537023002377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":47,"alternative-id":["S2589537023002377"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102060","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in risk for therapy-related myelodysplastic syndrome\/acute myeloid leukemia after initial chemo\/immunotherapy for common and rare lymphoid neoplasms, 2000\u20132018","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102060"}}